Methicillin-resistant Staphylococcus aureus (MRSA) Therapeutics - Pipeline Assessment and Market Forecasts to 2019 - PowerPoint PPT Presentation

View by Category
About This Presentation
Title:

Methicillin-resistant Staphylococcus aureus (MRSA) Therapeutics - Pipeline Assessment and Market Forecasts to 2019

Description:

“Methicillin-resistant Staphylococcus aureus (MRSA) Therapeutics - Pipeline Assessment and Market Forecasts to 2019”. The report is an essential source of information and analysis on the global Methicillin-Resistant Staphylococcus Aureus (MRSA) Therapeutics market. – PowerPoint PPT presentation

Number of Views:636
Slides: 9
Provided by: aarkresearch
Category: Other

less

Write a Comment
User Comments (0)
Transcript and Presenter's Notes

Title: Methicillin-resistant Staphylococcus aureus (MRSA) Therapeutics - Pipeline Assessment and Market Forecasts to 2019


1
Methicillin-resistant Staphylococcus aureus
(MRSA) Therapeutics - Pipeline Assessment and
Market Forecasts to 2019
  • Aarkstore Enterprise specialize in providing
    online market business information on market
    research reports, books, magazines, conference
    booking at competitive prices, and strive to
    provide excellent and innovative service to our
    customers.

2
Methicillin-resistant Staphylococcus aureus
(MRSA) Therapeutics - Pipeline Assessment and
Market Forecasts to 2019
  • Date 7 June 2012
  • Pages 112
  • Summary Methicillin-resistant Staphylococcus
    aureus (MRSA) Therapeutics - Pipeline Assessment
    and Market Forecasts to 2019. The report is an
    essential source of information and analysis on
    the global Methicillin-Resistant Staphylococcus
    Aureus (MRSA) Therapeutics market. The report
    identifies the key trends shaping and driving the
    global Methicillin-Resistant Staphylococcus
    Aureus (MRSA) Therapeutics market. The report
    also provides insights on the prevalent
    competitive landscape and the emerging players
    expected to significantly alter the market
    positioning of the current market leaders. Most
    importantly, the report provides valuable
    insights on the pipeline products within the
    global Methicillin-Resistant Staphylococcus
    Aureus (MRSA) Therapeutics sector. This report is
    built using data and information sourced from
    proprietary databases, primary and secondary
    research and in-house analysis by GlobalDatas
    team of industry experts. Scope The report
    provides information on the key drivers and
    challenges of the Methicillin-Resistant
    Staphylococcus Aureus (MRSA) Therapeutics market.
    Its scope includes -  - Annualized seven key
    markets (US, France, Germany, Italy, Spain, UK
    and Japan) Methicillin-Resistant Staphylococcus
    Aureus (MRSA) Therapeutics market revenues data
    from 2006 to 2011, forecast for eight years to
    2019.  - Pipeline analysis data providing a split
    across the different phases, mechanisms of action
    being developed and emerging trends by seven key
    markets. Pipeline candidates fall under major
    therapeutic classes. - Analysis of the current
    and future competition in the seven key countries
    Methicillin-Resistant Staphylococcus Aureus
    (MRSA) Therapeutics market.  - Insightful review
    of the key industry drivers, restraints and
    challenges. Each trend is independently
    researched to provide a qualitative analysis of
    its implications.  - Key topics covered include
    strategic competitor assessment, market
    characterization, unmet needs and the
    implications for the Methicillin-Resistant
    Staphylococcus Aureus (MRSA) Therapeutics
    market. - Analysis of key recent licensing and
    partnership agreements in Methicillin-Resistant
    Staphylococcus Aureus (MRSA) Therapeutics market 

3
Methicillin-resistant Staphylococcus aureus
(MRSA) Therapeutics - Pipeline Assessment and
Market Forecasts to 2019
  • Reasons to buy The report will enhance your
    decision making capability. It will allow you to
    -  - Develop and design your in-licensing and
    out-licensing strategies through a review of
    pipeline products and technologies and by
    identifying the companies with the most robust
    pipeline.  - Develop business strategies by
    understanding the trends shaping and driving the
    global Methicillin-Resistant Staphylococcus
    Aureus (MRSA) Therapeutics market.  - Drive
    revenues by understanding the key trends,
    innovative products and technologies, market
    segments and companies likely to impact the
    global Methicillin-Resistant Staphylococcus
    Aureus (MRSA) Therapeutics market in future.  -
    Formulate effective sales and marketing
    strategies by understanding the competitive
    landscape and by analyzing the performance of
    various competitors.  - Identify emerging players
    with potentially strong product portfolios and
    create effective counter-strategies to gain a
    competitive advantage.  - Organize your sales and
    marketing efforts by identifying the market
    categories and segments that present maximum
    opportunities for consolidations, investments and
    strategic partnerships.  - Whats the next big
    thing in the global Methicillin-Resistant
    Staphylococcus Aureus (MRSA) Therapeutics market
    landscape? Identify, understand and
    capitalize.  

4
1.1 List of Tables 5 1.2 List of Figures 6 2
Methicillin - resistant Staphylococcus aureus
(MRSA) Therapeutics - Introduction 8 2.1 Overview
8 2.1.1 Hospital-acquired MRSA (HA-MRSA) 8 2.1.2
Community-acquired MRSA (CA-MRSA) 8 2.1.3
Historical Aspect of MRSA Infection 9 2.1.4
Genetic Variance between CA-MRSA and HA-MRSA
9 2.2 Epidemiology 11 2.2.1 Historic
Epidemiology  (2006-2011) 11 2.2.2 Forecasted
Epidemiology  (2011-2019) 11 2.3 Prognosis 13 2.4
Etiology 13 2.5 Symptoms 14 2.6 Diagnosis
15 2.6.1 Bacterial Culture 15 2.6.2 ChromAgar
Technique 15 2.6.3 Latex Agglutination Test
15 2.6.4 Molecular Detection 15 2.7
Pathophysiology 16 2.7.1 Molecular Pathogenesis
of MRSA 16 2.7.2 Mechanism of Resistance 18 2.7.3
Transmission of MRSA 18 2.8 Treatment and
Management Pattern 19 2.9 Referral Pathway
22 2.10 GlobalData Pipeline Report Guidance 23 3
Methicillin - resistant Staphylococcus aureus
(MRSA) Therapeutics - Market Characterization
24 3.1 MRSA Therapeutics Market Size (2006-2011)
- Global 24 3.2 MRSA Therapeutics Market Forecast
(2011-2019) - Global 26 3.3 MRSA Therapeutics
Market Size (2006-2011) - The US 28 3.4 MRSA
Therapeutics Market Forecast (2011-2019) - The US
29 3.5 MRSA Therapeutics Market Size (2006-2011)
- France 30 3.6 MRSA Therapeutics Market Forecast
(2011-2019) - France 31 3.7 MRSA Therapeutics
Market Size (2006-2011) - Germany 32 3.8 MRSA
Therapeutics Market Forecast (2011-2019) -
Germany 33
5

3.9 MRSA Therapeutics Market Size (2006-2011) -
Italy 35 3.10 MRSA Therapeutics Market Forecast
(2011-2019) - Italy 36 3.11 MRSA Therapeutics
Market Size (2006-2011) - Spain 38 3.12 MRSA
Therapeutics Market Forecast (2011-2019) - Spain
39 3.13 MRSA Therapeutics Market Size (2006-2011)
- The UK 41 3.14 MRSA Therapeutics Market
Forecast (2011-2019) - The UK 42 3.15 MRSA
Therapeutics Market Size (2006-2011) - Japan
44 3.16 MRSA Therapeutics Market Forecast
(2011-2019) - Japan 45 3.17 Drivers and Barriers
for the MRSA Therapeutics Market 46 3.17.1
Drivers for the MRSA Therapeutics Market
46 3.17.2 Barriers for the MRSA Therapeutics
Market 46 3.18 Opportunity and Unmet Need 48 3.19
Key Takeaway 51 4 Methicillin - resistant
Staphylococcus aureus (MRSA) Therapeutics - -
Competitive Assessment 52 4.1 Overview 52 4.2
Strategic Competitor Assessment 52 4.3 Product
Profile for the Major Marketed Products in the
MRSA Therapeutics Market 54 4.3.1 Zyvox
(linezolid) 54 4.3.2 Cubicin (daptomycin)
55 4.3.3 Tygacil (tigecycline) 57 4.3.4 Vibativ
(telavancin) 58 4.3.5 Teflaro (ceftaroline)
59 4.3.6 Vancocin (vancomycin) 61 4.4 Key
Takeaway 63 5 Methicillin - resistant
Staphylococcus aureus (MRSA) Therapeutics -
Pipeline Assessment 64 5.1 Overview 64 5.2
Strategic Pipeline Assessment 64 5.3 MRSA
Therapeutics- Pipeline Analysis by Phase of
Development 65 5.3.1 MRSA Therapeutics- Phase III
Pipeline 65 5.3.2 MRSA Therapeutics- Phase II
Pipeline 66 5.3.3 MRSA Therapeutics- Phase I
Pipeline 67 5.3.4 MRSA Therapeutics- Pre-Clinical
Pipeline 68 5.3.5 MRSA Therapeutics- Discovery
Pipeline 69
6

5.3.6 MRSA Therapeutics- Unknown Phase Pipeline
70 5.4 MRSA Therapeutics- Pipeline by Mechanism
of Action 71 5.5 Technology Trends Analytical
Framework 73 5.6 Most Promising Drug Profiles
74 5.6.1 Torezolid phosphate (TR-701, Tedizolid)
74 5.6.2 Ceftobiprole Medocaril 75 5.6.3
Dalbavancin 76 5.6.4 Oritavancin 77 5.7 Key
Takeaway 77 6 Methicillin - resistant
Staphylococcus aureus (MRSA) Therapeutics
-Clinical Trials Mapping 78 6.1 Clinical Trials
by Region and Country 78 6.2 Clinical Trials by
Phase of Clinical Development 79 6.3 Clinical
Trials by Trial Status 80 6.4 Clinical Trials by
Sponsors 81 6.5 Top Companies Participating in
MRSA Clinical Trials 83 7 Methicillin - resistant
Staphylococcus aureus (MRSA) Therapeutics -
Strategic Assessment 84 7.1 Key Events Impacting
the Future Market 84 7.2 Future Market
Competition Scenario 85 8 Methicillin - resistant
Staphylococcus aureus (MRSA) Therapeutics -
Future Players 87 8.1 Introduction 87 8.2 Company
Profiles 88 8.2.1 Basilea Pharmaceutica Ltd.
88 8.2.2 Durata Therapeutics, Inc. 89 8.2.3 The
Medicines Company 89 8.2.4 Trius Therapeutics,
Inc. 90 8.2.5 AstraZeneca PLC 91 8.2.6
GlaxoSmithKline plc 93 8.2.7 Rib-X
Pharmaceuticals, Inc. 94 8.2.8 Wockhardt Limited
95 8.3 Details of Other Companies in the Pipeline
97 8.4 Key Takeaway 100 9 Methicillin - resistant
Staphylococcus aureus (MRSA) Therapeutics -
Licensing and Partnership Deals 101 10 KOL
Insights 104 11 Methicillin - resistant
Staphylococcus aureus (MRSA) Therapeutics -
Appendix 105 11.1 Definitions 105 11.2
Abbreviations 105
7
  • For more information, please visit
  • http//www.aarkstore.com/reports/Methicillin-resis
    tant-Staphylococcus-aureus-MRSA-Therapeutics-Pipel
    ine-Assessment-and-Market-Forecasts-to-2019-209429
    .html Or email us at contact_at_aarkstore.com or
    call 919272852585
  • Related Reports
  • Vemurafenib - Comprehensive patent
    search  Colesevelam - Comprehensive patent
    search  Rifaximin - Comprehensive patent
    search  Nevirapine - Comprehensive patent
    search  Liraglutide - Comprehensive patent
    search  Vilazodone - Comprehensive patent
    search  Hexylaminolevulinic Acid - Comprehensive
    patent search  Treprostinil - Comprehensive
    patent search  Patient Adherence, Communication
    and Engagement (PACE) - Increased Investment and
    Adoption of New Digital Tools Enable Key
    Stakeholder Collaborations and Encourage
    Compliance  Express Scripts, Inc.
    Pharmaceuticals and Healthcare Company Profile,
    SWOT and Financial Report

8
Contact Us
  • Aarkstore Enterprise
  • Tel 912227453309
  • Mobile No08149852585
  • Email contact_at_aarkstore.com
  • Website http//www.aarkstore.com
  • Blog http//www.emarketreports.com
  • http//teju-aarkstoreenterprise.blogspot.in
  • Follow us on twitter http//twitter.com/aarkstore
    dotcom
  • http//in.linkedin.com/in/aarkstore
  • http//www.facebook.com/aarkstoreenterprise
About PowerShow.com